NATERA INC

NASDAQ: NTRA (Natera, Inc.)

Kemas kini terakhir: 01 Mar, 12:05PM

208.04

-8.06 (-3.73%)

Penutupan Terdahulu 216.10
Buka 211.02
Jumlah Dagangan 2,156,496
Purata Dagangan (3B) 1,158,830
Modal Pasaran 29,010,993,152
Harga / Jualan (P/S) 11.69
Harga / Buku (P/B) 16.32
Julat 52 Minggu
125.38 (-39%) — 256.36 (23%)
Tarikh Pendapatan 7 May 2026
Margin Keuntungan -10.36%
Margin Operasi (TTM) -15.78%
EPS Cair (TTM) -1.47
Pertumbuhan Hasil Suku Tahunan (YOY) 36.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 15.78%
Nisbah Semasa (MRQ) 3.87
Aliran Tunai Operasi (OCF TTM) 153.12 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 120.93 M
Pulangan Atas Aset (ROA TTM) -8.87%
Pulangan Atas Ekuiti (ROE TTM) -18.66%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Diagnostics & Research (US) Bercampur Menaik
Diagnostics & Research (Global) Bercampur Menaik
Stok Natera, Inc. Menurun Menaik

AISkor Stockmoo

0.7
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam 0.0
Volatiliti Harga 2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 0.70

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
NTRA 29 B - - 16.32
IDXX 51 B - 48.70 30.28
MEDP 13 B - 29.68 28.80
ILMN 22 B - 31.76 7.46
ICLR 8 B - 14.30 0.900
EXAS 19 B - - 8.25

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Sektor Healthcare
Industri Diagnostics & Research
Gaya Pelaburan Mid Growth
% Dimiliki oleh Orang Dalam 3.24%
% Dimiliki oleh Institusi 96.37%

Pemilikan

Nama Tarikh Syer Dipegang
Duquesne Family Office Llc 31 Dec 2025 2,511,357
Castle Hook Partners Lp 31 Dec 2025 2,167,869
Julat 52 Minggu
125.38 (-39%) — 256.36 (23%)
Julat Harga Sasaran
215.00 (3%) — 300.00 (44%)
Tinggi 300.00 (Citigroup, 44.20%) Beli
Median 260.00 (24.98%)
Rendah 215.00 (Wells Fargo, 3.35%) Pegang
Purata 263.00 (26.42%)
Jumlah 8 Beli, 1 Pegang
Harga Purata @ Panggilan 223.93
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Morgan Stanley 03 Mar 2026 250.00 (20.17%) Beli 207.04
Baird 27 Feb 2026 257.00 (23.53%) Beli 208.04
Evercore ISI Group 27 Feb 2026 260.00 (24.98%) Beli 208.04
Wells Fargo 27 Feb 2026 215.00 (3.35%) Pegang 208.04
15 Dec 2025 205.00 (-1.46%) Pegang 228.40
Citigroup 07 Jan 2026 300.00 (44.20%) Beli 254.40
Guggenheim 05 Jan 2026 270.00 (29.78%) Beli 237.42
Canaccord Genuity 22 Dec 2025 285.00 (36.99%) Beli 235.57
Barclays 15 Dec 2025 270.00 (29.78%) Beli 228.40
JP Morgan 15 Dec 2025 260.00 (24.98%) Beli 228.40
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
BROPHY MICHAEL BURKES 208.04 - 10,051 2,091,010
CHAPMAN STEVEN LEONARD 208.04 200.17 33,451 6,990,233
FESKO JOHN 208.04 - 10,051 2,091,010
MOSHKEVICH SOLOMON 208.04 200.17 7,051 1,490,500
RABINOWITZ DANIEL 208.04 - 12,272 2,553,067
RABINOWITZ MATTHEW 208.04 - 29,920 6,224,557
SHEENA JONATHAN 208.04 200.17 -967 -177,014
Jumlah Keseluruhan Kuantiti Bersih 101,829
Jumlah Keseluruhan Nilai Bersih ($) 21,263,363
Purata Pembelian Keseluruhan ($) 208.04
Purata Jualan Keseluruhan ($) 200.17
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
CHAPMAN STEVEN LEONARD Pegawai 02 Mar 2026 Jual automatik (-) 3,950 200.17 790,672
MOSHKEVICH SOLOMON Pegawai 02 Mar 2026 Jual automatik (-) 3,000 200.17 600,510
MOSHKEVICH SOLOMON Pegawai 02 Mar 2026 Pelaksanaan pilihan 5,125 - -
SHEENA JONATHAN Pengarah 02 Mar 2026 Jual automatik (-) 3,070 200.17 614,522
FESKO JOHN Pegawai 27 Feb 2026 Diperolehi (+) 10,051 208.04 2,091,010
BROPHY MICHAEL BURKES Pegawai 27 Feb 2026 Diperolehi (+) 10,051 208.04 2,091,010
RABINOWITZ MATTHEW Pegawai 27 Feb 2026 Diperolehi (+) 29,920 208.04 6,224,557
RABINOWITZ DANIEL Pegawai 27 Feb 2026 Diperolehi (+) 12,272 208.04 2,553,067
CHAPMAN STEVEN LEONARD Pegawai 27 Feb 2026 Diperolehi (+) 37,401 208.04 7,780,904
MOSHKEVICH SOLOMON Pegawai 27 Feb 2026 Diperolehi (+) 10,051 208.04 2,091,010
SHEENA JONATHAN Pengarah 27 Feb 2026 Diperolehi (+) 2,103 208.04 437,508
Papar semua
Tarikh Jenis Butiran
06 Feb 2026 Pengumuman Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
02 Feb 2026 Pengumuman Natera Submits Signatera™ CDx PMA to FDA
28 Jan 2026 Pengumuman Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
26 Jan 2026 Pengumuman Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
21 Jan 2026 Pengumuman Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
20 Jan 2026 Pengumuman Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
13 Jan 2026 Pengumuman Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
12 Jan 2026 Pengumuman Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
11 Jan 2026 Pengumuman Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
07 Jan 2026 Pengumuman Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
05 Jan 2026 Pengumuman Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
05 Jan 2026 Pengumuman Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
22 Dec 2025 Pengumuman Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
18 Dec 2025 Pengumuman Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
16 Dec 2025 Pengumuman I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
12 Dec 2025 Pengumuman Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
10 Dec 2025 Pengumuman Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda